Literature DB >> 2839576

Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.

N Singh1, J S Dummer, S Kusne, M K Breinig, J A Armstrong, L Makowka, T E Starzl, M Ho.   

Abstract

One hundred twenty-one adult liver transplant recipients were studied for the incidence, risk factors, and morbidity associated with herpesviruses infections after transplantation. The overall incidence of infection was 59% for cytomegalovirus (CMV), 35% for herpes simplex virus (HSV), 25% for Epstein-Barr virus (EBV), and 7% for varicella-zoster virus (VZV). Primary CMV infection occurred in 46% and reactivation CMV infection in 67% of the susceptible recipients. Symptomatic and disseminated CMV diseases were more common when patients developed primary infection (P less than .01, for both comparisons). The donor organ appeared to be the only important source of CMV infection in seronegative recipients. The use of OKT3 antibodies was associated with disseminated CMV disease in patients with primary infection (P = .04) but not with reactivation infection (P greater than .10). Although most HSV infections were oral or genital reactivations, three cases of HSV hepatitis occurred--one was a primary infection. Symptomatic reactivations of HSV were observed in 53% of HSV-seropositive recipients who received OKT3, versus 31% of seropositive recipients who did not receive OKT3 (P = .05).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839576      PMCID: PMC2976493          DOI: 10.1093/infdis/158.1.124

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  The impact of cyclosporine therapy on the occurrence of infection in the renal transplant recipient.

Authors:  N E Tolkoff-Rubin; R H Rubin
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

2.  Transmission of fatal herpes simplex infection through renal transplantation.

Authors:  B Koneru; A G Tzakis; L E DePuydt; A J Demetris; J A Armstrong; J S Dummer; T E Starzl
Journal:  Transplantation       Date:  1988-03       Impact factor: 4.939

3.  Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation.

Authors:  M K Breinig; B Zitelli; T E Starzl; M Ho
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

4.  A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies.

Authors:  F K Lee; L Pereira; C Griffin; E Reid; A Nahmias
Journal:  J Virol Methods       Date:  1986-09       Impact factor: 2.014

5.  Transmission of infection with herpes simplex virus by renal transplantation.

Authors:  J S Dummer; J Armstrong; J Somers; S Kusne; B J Carpenter; J T Rosenthal; M Ho
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

6.  Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.

Authors:  M J Bia; W Andiman; K Gaudio; A Kliger; N Siegel; D Smith; W Flye
Journal:  Transplantation       Date:  1985-12       Impact factor: 4.939

7.  Detection of herpes simplex virus type 2-specific antibody with glycoprotein G.

Authors:  F K Lee; R M Coleman; L Pereira; P D Bailey; M Tatsuno; A J Nahmias
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

8.  Acquisition of donor strains of cytomegalovirus by renal-transplant recipients.

Authors:  S W Chou
Journal:  N Engl J Med       Date:  1986-05-29       Impact factor: 91.245

9.  Blood use in liver transplantation.

Authors:  J H Lewis; F A Bontempo; F Cornell; J E Kiss; P Larson; M V Ragni; E O Rice; J A Spero; T E Starzl
Journal:  Transfusion       Date:  1987 May-Jun       Impact factor: 3.157

10.  Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine.

Authors:  J S Dummer; L T White; M Ho; B P Griffith; R L Hardesty; H T Bahnson
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

View more
  57 in total

1.  Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation.

Authors:  I G Sia; J A Wilson; M J Espy; C V Paya; T F Smith
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients.

Authors:  R Delgado; C Lumbreras; C Alba; M A Pedraza; J R Otero; R Gómez; E Moreno; A R Noriega; C V Payá
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

3.  Risk factors for viral reactivation following bone marrow transplantation.

Authors:  D Pillay; A Webster; H G Prentice; P D Griffiths
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Infections in pediatric liver recipients treated for acute rejection.

Authors:  B Koneru; V P Scantlebury; L Makowka; C O Esquivel; S Todo; A G Tzakis; J W Marsh; S Iwatsuki; L Douglas; T E Starzl
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

6.  Infections with FK 506 immunosuppression: preliminary results with primary therapy.

Authors:  M Alessiani; S Kusne; F M Martin; J J Fung; A Jain; S Todo; R Simmons; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

7.  Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report.

Authors:  L A Mieles; J J Fung; I Yokoyama; J McCauley; N Singh; S Todo; R D Gordon; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression.

Authors:  M Alessiani; S Kusne; J J Fung; J Torre-Cisneros; A Jain; K Abu-Elmagd; S Takaya; U Cillo; M Martin; S Todo
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Histological diagnosis of cytomegalovirus hepatitis in liver allografts.

Authors:  F Colina; N T Jucá; E Moreno; C Ballestín; J Fariña; M Nevado; C Lumbreras; R Gómez-Sanz
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

10.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.